Paul Peter Tak, M.D., Ph.D., FMedSci

2023

In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $1.5M as Chief Executive Officer at Candel Therapeutics, a 20% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$134,000
Option Awards$189,558
Salary$670,000
Stock Awards$176,506
Other$314,695
Total$1,484,759

FMedSci received $670K in salary, accounting for 45% of the total pay in 2023.

FMedSci also received $134K in non-equity incentive plan, $189.6K in option awards, $176.5K in stock awards and $314.7K in other compensation.

Rankings

In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 792nd out of 2,918 executives tracked by ExecPay. In other words, FMedSci earned more than 72.9% of executives.

ClassificationRankingPercentile
All
792
out of 2,918
73rd
Division
Manufacturing
469
out of 1,608
71st
Major group
Chemicals And Allied Products
320
out of 901
65th
Industry group
Drugs
312
out of 864
64th
Industry
Biological Products, Except Diagnostic Substances
99
out of 211
53rd
Source: SEC filing on May 30, 2024.

FMedSci's colleagues

We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2023.

2023

Francesca Barone

Candel Therapeutics

Chief Scientific Officer

2023

Jason Amello

Candel Therapeutics

Chief Financial Officer

News

You may also like